ID   PPMI.I.1079.3
AC   CVCL_D5SA
SY   PPMI41568; PPMI_41568; CDIi105-A; FCDI_14555
DR   BioSamples; SAMEA115473944
DR   hPSCreg; CDIi105-A
DR   Wikidata; Q127383397
RX   PubMed=34434090;
WW   https://www.ppmi-info.org/access-data-specimens/download-data
WW   https://www.michaeljfox.org/sites/default/files/media/document/2018%20-%20PDTC%20-%20NKP%20Poster%20on%20iPSCs.pdf
CC   Part of: Parkinson's Progression Markers Initiative (PPMI) cell line panel.
CC   Population: Hispanic.
CC   Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Heterozygous (from autologous cell line PPMI.I.1079.1).
CC   Miscellaneous: PPMI study cohort PD, PPMI study subgroup LRRK2.
CC   Caution: The PPMI41568 and PPMI_41568 identifiers correspond to an internal donor ID at PPMI. As multiple iPSC clones have been established from the cells of this donor, these identifiers should not be cited in a publication. Note that FujiFilm Cellular Dynamics, Inc (FCDI) and hPSCreg have assigned only a single identifier for all of the PBMC derived clones.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C198605; Parkinson disease 8, autosomal dominant
DI   ORDO; Orphanet_411602; Hereditary late-onset Parkinson disease
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_D5S8 ! PPMI.I.1079.1
OI   CVCL_D5S9 ! PPMI.I.1079.2
SX   Male
AG   65-69Y
CA   Induced pluripotent stem cell
DT   Created: 02-05-24; Last updated: 10-09-24; Version: 2
//
RX   PubMed=34434090; DOI=10.3389/fnmol.2021.734273; PMCID=PMC8381147;
RA   Nguyen D., Bharat V., Conradson D.M., Nandakishore P., Wang X.-N.;
RT   "Miro1 impairment in a Parkinson's at-risk cohort.";
RL   Front. Mol. Neurosci. 14:734273.1-734273.8(2021).
//